Screener
IDNA vs IBB
iShares Genomics Immunology and Healthcare ETF vs iShares Biotechnology ETF
Key differences
- IBB is significantly larger than IDNA — larger funds tend to be more liquid and less likely to close.
- Over the last 3 years, IBB has delivered higher annualized returns.
- IBB has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| IDNA | IBB | |
|---|---|---|
| Annual cost (TER) | 0.47% | 0.44% |
| Fund size (AUM) | $160M | $7.9B |
| Since | 2019 | 2001 |
| Dividend yield | 1.05% | 0.23% |
| Asset class | equity | equity |
| Region | — | north america |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +49.2% | +39.0% |
| CAGR 3Y | +8.0% | +9.6% |
| CAGR 5Y | -7.5% | +2.7% |
| Sharpe 3Y | 0.29 | 0.38 |
| Volatility 1Y | 24.43% | 19.75% |
| Max drawdown | -68.26% | -39.82% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to IDNA and IBB
Explore further